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1. Introduction
During the last decade there was accumulating evidence
. that alterations of excitation-contraction EC coupling may
play a critical role in the pathophysiology of myocardial
failure. EC-coupling comprises processes involved in cal-
cium activation of contractile proteins and the subsequent
 removal of calcium facilitating relaxation for review see
wx . 1 . The initial event is depolarisation of the membrane
which opens voltage-gated, dihydropyridine-sensitive sar-
. colemmal calcium channels dihydropyridine receptors
allowing an influx of calcium into the myocyte. There is a
close proximity between one or a few sarcolemmal cal-
cium channels and one or a few calcium channels of the
. sarcoplasmic reticulum ryanodine receptors . This may
enable calcium influx through one opening of a single
sarcolemmal calcium channel to increase a local pool of
calcium sufficiently to open adjacent ryanodine receptors
to release calcium. This local, punctate, increase of cal-
cium is termed calcium spark according to its visualization
wx by confocal microscopy 2 . It is the sum of these local
calcium releases which generate a global cytoplasmic in-
crease in calcium which causes activation of contractile
proteins. The global increase in calcium is immediately
followed by calcium removal resulting in subsequent deac-
tivation of the contractile machinery. Calcium removal
from the cytosol occurs by activity of the sarcoplasmic
reticulum calcium pump and by exchange of calcium for
q 2q wx sodium by the sarcolemmal Na -Ca -exchanger 1 .
Defective EC-coupling in heart failure may result from
altered density or function of proteins relevant for calcium
homeostasis. Knowledge of these alterations is a pre-
) . . Corresponding author. Tel. q49-761 270 3591; Fax q49-761
270 3788; E-mail: hasenfus@ruf.uni-freiburg.de
requisite for understanding the pathophysiology of myocar-
dial failure and for the development of new strategies to
treat patients with heart failure. This review focuses on
expression and function of calcium-regulatory proteins in
failing myocardium from animal models of heart failure
and from failing human hearts.
2. Sarcolemmal L-type calcium channels
Calcium entry through voltage-gated L-type calcium
channels is the key event causing the transition from the
wx resting state of the myocardium to contraction 3 . Sar-
colemmal calcium channels are multimeric protein com-
plexes comprised of five subunits termed a , a , b, g, d, 12
 wx . which are encoded by separate genes for review see 4 .
The a -subunit contains the calcium conducting pore and 1
the binding sites for calcium channel blockers. The a rb-, 2
g-, and d-subunits have regulatory properties. The g-sub-
unit is only expressed in skeletal muscle. At least three
genes code for the dihydropyridine-sensitive a -subunits 1
in skeletal, neuronal and cardiacrsmooth muscle tissue.
The cardiac and smooth muscle L-type calcium channel
wx a -subunits are splice variants of the same gene 4 . 1
2.1. L-type calcium channels in animal models of heart
failure
Several studies have examined changes in the density of
L-type calcium channels in myocardium from cardiomyo-
pathic hamsters, a genetic cardiomyopathy model with the
prominent characteristics of abnormal calcium homeostasis
Time for primary review 27 days.
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. Table 1 . In this model, alterations in the density of the
channels seem to depend on age of the animal or stage of
 wx . the disease for review see 5 . When there is fully
developed morphological and hemodynamic evidence of
myopathy, there seems to be no appreciable difference
between control and myopathic hamsters as measured by
wx antagonist binding 6 . In contrast, the number of dihydro-
pyridine receptors seems to be increased in younger car-
diomyopathic animals before morphological evidence for
wx the myopathy is present 7 .
The density of L-type calcium channels, as evaluated by
antagonist binding was shown to be decreased in moderate
to severe stages of congestive heart failure in rats follow-
wx ing myocardial infarction 8,9 and in mongrel dogs with
myocardial failure following intracoronary microemboliza-
. wx w 3 x tion Table 1 10 . Similarly, H nitrendipine binding was
wx decreased in a rabbit tachycardia heart failure model 11 .
In contrast, dihydropyridine binding was not altered in a
wx tachycardia failure dog model 12 .
2.2. L-type calcium channels in failing human myocardium
Abundance of the L-type calcium channel a -subunit in 1
failing and nonfailing human myocardium has been stud-
ied by Northern blot analysis and by dihydropyridine
binding. Takahashi et al. reported a significant decrease in
mRNA levels encoding the dihydropyridine receptor as
well as a decrease in dihydropyridine binding sites in
failing human hearts with dilated and ischemic cardiomy-
wx opathy 13 . This is in contrast to findings by Rasmussen et
al. which indicate that dihydropyridine binding sites are
not significantly altered in the human ventricular tissue
wx from hearts with end-stage dilated cardiomyopathy 14 .
Unaltered levels of the a -subunit of L-type calcium 1
channels would be consistent with functional measure-
ments indicating that calcium current densities, measured
during basal conditions, are similar in isolated myocytes
from failing hearts with dilated cardiomyopathy and from
wx nonfailing hearts 15,16 . However, measurements by Piot
et al. recently suggested that function of L-type calcium
wx channels may be altered in human heart failure 17 . They
observed that increasing frequencies augment calcium cur-
rents in myocytes from nonfailing hearts, whereas high
frequency upregulation of calcium currents was attenuated
or lost in myocytes from hearts with reduced left ventricu-
lar function. These findings may indicate that quantitative
or qualitative changes of subunits other than the a -sub- 1
unit of the multimeric L-type calcium channel may occur
in the failing human heart.
3. Sarcoplasmic reticulum calcium release channels
Intracellular calcium release channels, located on the
sarcoplasmic reticulum are among the largest proteins
identified to date. Two different types of channels are
. known termed ryanodine receptor RyR and inositol
. 1,4,5-trisphosphate receptor IP3R . In the cardiac sarco-
plasmic reticulum, the density of the RyR is significantly
higher than that of the IP3R, and the former is far more
 relevant for excitation-contraction coupling for review see
wx . 18 . The calcium sensitive RyR which is located in the
immediate vicinity of the L-type calcium channel is acti-
vated by a local increase in calcium subsequent to transsar-
wx colemmal calcium influx 2 . Once activated, the channel
opens and releases calcium for activation of contractile
wx proteins 1,19,20 . This process is termed calcium-induced
wx calcium release 3 . The RyR forms a tetrameric structure
wx comprised of four monomers 20 . Molecular cloning anal-
ysis has revealed that two distinct genes encode the cardiac
. . RyR2 and skeletal muscle RyR1 specific receptors
wx . 21,22 . A third type of ryanodine receptor RyR3 exhibits
functional properties distinct from those of RyR1 and
wx RyR2 23 . The tetrameric structure of RyR is stabilized by
a channel-associated protein known as the FK506 binding
. protein FKBP . The immunosuppressant drugs rapamycin
and FK506 can dissociate FKBP from RyRs which in-
wx creases the sensitivity of RyRs to agonists 18 .
3.1. Ryanodine receptors in failing animal myocardium
In the cardiomyopathic hamster, Finkel et al. reported
w3 x an increase in H ryanodine binding to cardiac membrane
wx fractions prepared from 1–2 months old animals 24 . In
contrast, a decreased number of ryanodine receptors as
w3 x measured by H ryanodine binding and mRNA levels
compared to control hamsters has been reported from
wx measurements in crude membrane fractions 25 .
Table 1
Quantification of L-type calcium channels in animal models of heart failure
Animal model Channel density Method Reference
3 wx w x Syrian hamster n.s. H nitrendipine binding Finkel et al. Life Sciences 41;1987 6
3 wx w x idem ® H dihydropyridine binding Wagner et al. Science 232;1986 7
3 wx w x Rat, infarction y H nitrendipine binding Dixon et al. Circ. Res. 66;1990 8
3 wx wx idem y H PN 200110 binding Gopalakrishnan et al. Am. J. Physiol. 261;1991 9
3 wx w x Dog, infarction y H nitrendipine binding Gengo et al. J. Mol. Cell. Cardiol. 24;1992 10
3 wx w x Rabbit, tachycardia pacing y H nitrendipine binding Colston et al. Cell. Calcium 16;1994 11
3 wx w x Dog, pacing tachycardia n.s. H dihydropyridine binding Vatner et al. Circulation 90;1994 12
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A decreased number and activity of RyRs has also been
observed in two distinct types of dog failure models; a
spontaneous occurring cardiomyopathy in dobermans, and
a rapid ventricular pacing failure model of mongrels
wx 26,27 . Consistently, Vatner et al. showed that in the dog
w3 x pacing tachycardia failure model H ryanodine binding
was depressed as early as 1 day after pacing and remained
at this depressed level up to 4–7 weeks of pacing when
wx heart failure was manifest 12 . A decreased number of
ryanodine receptors was also observed in chronic doxoru-
wx bicin cardiomyopathy in rabbits 28 .
Interestingly, in a recent study performed in hyperten-
sive and failing rats, Gomez at al. suggested that calcium ´
current density as well as density and function of RyRs are
normal in this model. However, they showed that the
relationship between calcium current density and the prob-
ability of evoking a spark was reduced indicating that
calcium influx is less effective at inducing SR calcium
wx release 29 .
3.2. Ryanodine receptors in failing human myocardium
Several groups have studied mRNA expression of the
RyR in human heart failure and results have not been
. consistent Table 2 . While Brillantes et al. observed de-
creased mRNA levels in ischemic but not in dilated car-
diomyopathy, Go et al. described a reduction of RyR
mRNA levels in both ischemic and dilated cardiomyopathy
wx 30,31 .
In three studies a radioligand binding assay was used.
 Go et al. in a small number of samples and without any
. statistical analysis observed that high affinity binding sites
w3 x for H ryanodine were decreased by about 30% in left
wx ventricular myocardium from failing human hearts 31 .
w3 x Schumacher et al. observed no differences in H ryano-
wx dine binding between failing and nonfailing hearts 36 .
Finally, Sainte Beuve observed an increase of RyRs in
wx failing hearts 33 .
At the level of the protein, no change in RyR levels
between failing and nonfailing hearts were consistently
wx observed in three different studies 33–35 . From their
findings of unchanged protein levels but increased
w3 x H ryanodine binding in failing hearts, Sainte Beuve et al.
suggested that ryanodine binding properties may be af-
fected in failing myocardium which may reflect altered
wx channel activity 33 .
Altered function of RyRs was also suggested from
wx D’Agnolo et al. 37 . They found that caffeine threshold of
the ryanodine receptor was increased, suggesting impaired
gating mechanism of the calcium release channel in dilated
wx cardiomyopathy 37 . Furthermore, Nimer et al. reported
differences in response to ryanodine between failing and
nonfailing myocardium which may also reflect altered
wx function of the RyRs 38 . In contrast, Holmberg and
Williams who studied activity of single RyR under volt-
age-clamp conditions reported normal basal properties of
wx the RyR from failing human hearts 39 .
3.3. IP3R in failing myocardium
 Like the RyR, the IP3R has a tetrameric structure for
wx . reviews see 18 . Three different isoforms have been
identified so far. It was shown that IP3Rs are expressed in
myocytes and that activation by the second messenger
. inositol 1,4,5-trisphosphate IP3 results in calcium release
wx from the sarcoplasmic reticulum 40 . IP3 is generated by
phosphoinositide hydrolysis following activation of G-pro-
tein coupled a-receptors, AII-receptors and endothelin-re-
ceptors. This type of activation of intracellular calcium
wx release is referred to as pharmacomechanical coupling 18 .
It was recently observed that IP3R mRNA levels are
wx significantly increased in failing human myocardium 31 .
w3 x Although in the study by Go et al. H IP3 binding sites
were not significantly increased in failing compared to
nonfailing myocardium in a small number of samples, it
was emphasized that the number of IP3Rs increases signif-
icantly relative to that of ryanodine receptors in the failing
wx human myocardium 31 . The functional relevance of this
Table 2
2q . Quantification of SR-Ca -release channels RYR in human heart failure
Quantity Disease Method Reference
wx 28%y ICM Northern blot Brillantes et al. Circ. Res. 71;1992 30
n.s. DCM Northern blot idem
wx 31%y DCM, ICM Northern blot Go et al. J. Clin. Invest. 95;1995 31
wx Inverse Relation With ANF DCM Northern blot Arai et al. Circ. Res. 72;1993 32
wx 30% y DCM Northern blot Sainte Beuve et al. J. Mol. Cell. Cardiol. 29;1997 33
n.s. ICM Northern blot idem
wx n.s. DCM Western blot Meyer et al. Circulation 92;1995 34
wx n.s. ICM Western blot Schillinger et al. Mol. Cell. Biochem. 160r161; 1996 35
wx n.s. DCM, ICM Western blot Sainte Beuve et al. J. Mol. Cell. Cardiol. 29;1997 33
3 wx 70–114%® DCM, ICM H ryanodine binding idem
3 wx wx n.s. DCM, ICM H ryanodine binding Schumacher et al. Naunyn-Schmiedebergs Arch. Pharm. 353;1995 36
ANFsatrial natriuretic factor; DCMsdilated cardiomyopathy; ICMsischemic cardiomyopathy; RYRsryanodine receptor; n.s.sno significant change
versus nonfailing human myocardium.
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alteration is unknown. It was speculated that IP3Rs could
be involved in regulation of diastolic tone and signaling
 wx . pathways in the heart for review see 18 .
4. Sarcoplasmic reticulum calcium storage proteins
Calsequestrin and calreticulin are located within the
wx lumen of the SR 41–43 . Calsequestrin, a high-capacity
moderate affinity calcium-binding protein is primarily re-
sponsible for the calcium storage capacity of the SR in
wx cardiac muscle 41 . Two distinct isoforms of calsequestrin
have been identified. The skeletal muscle isoform ex-
pressed in both fast- and slow-twitch skeletal muscle, and
the cardiac isoform, expressed predominantly in the heart
wx 44,45 .
Calreticulin is a major calcium binding protein of non-
 muscle endoplasmic reticulum membranes for review see
wx . 43 . In addition to its apparent calcium storage role,
evidence is accumulating which suggests that calreticulin
has other regulatory functions within the cell. It may be
involved in regulation of DNA-synthesis and protein-
wx synthesis 43,46 .
4.1. Calsequestrin in failing myocardium
Calsequestrin expression has been shown to be un-
changed during ontogenic development and aging as well
as in hypertrophied myocardium due to pressure overload
wx and hyper- or hypothyrosis 47,48 .
Studies in failing human myocardium consistently
showed unchanged mRNA and protein levels as compared
wx to nonfailing myocardium 13,32,34,35,49 . Similarly, cal-
reticulin protein levels were shown to be unchanged in the
wx failing human hearts 34 .
5. Sarcoplasmic reticulum calcium pump and phospho-
lamban
Calcium transport into the SR occurs by SR-Ca
2q-
ATPase, which transports two calcium ions per molecule
of high-energy phosphate hydrolyzed against a high ion
gradient from a free intracellular calcium between 100 nM
wx and 10 mM to a free calcium in the SR ;1 mM 41,50 .
This pump, together with the Na
q-Ca
2q-exchanger and the
sarcolemmal calcium-ATPase, eliminates calcium from the
cytosol in order to facilitate relaxation of the myocardium
wx 2q 1,50 . Moreover, SR-Ca -ATPase is crucial for calcium
accumulation within the SR and thus, for the availability of
calcium for systolic release through the RyRs. Sarco-endo-
plasmic reticulum Ca
2q-ATPases are encoded by three
genes and five different isoforms are expressed: the adult
. fast-twitch skeletal muscle isoform SERCA1a , its alterna-
. tively spliced neonatal isoform SERCA1b , the
. cardiacrslow-twitch skeletal muscle isoform SERCA2a ,
its alternative spliced smooth musclernonmuscle isoform
. SERCA2b , and an isoform expressed in a broad variety
.  of muscle and nonmuscle tissues SERCA3 for review
wx . see 51 . No isoform shift has been detected in the failing
wx heart 51 .
The SR-Ca
2q-ATPase is regulated by phospholamban
wx 41,52,53 . Dephosphorylated phospholamban is an in-
hibitor of the SR-Ca
2q-ATPase activity. The inhibition has
been suggested to involve direct protein-protein interaction
followed by conformational changes in the SR-Ca
2q-
ATPase resulting in a decrease in the affinity of the
wx calcium pump for calcium 53–55 . It has been recognized
that phosphorylation of phospholamban by
 calciumrcalmodulin-dependent protein kinase CaM ki-
. . nase; Thr 17 and by protein kinase A Ser 16 results in
2q wx stimulation of SR-Ca -ATPase 52,54,56 .The molecular
mechanism of SR-Ca
2q-ATPase stimulation by phospho-
lamban phosphorylation is thought to involve primarily an
increase in the affinity of the SR-Ca
2q-ATPase for cal-
wx cium, although an increase in V may also occur 56–58 . max
Furthermore, direct phosphorylation of SR-Ca
2q-ATPase
. Ser 38 by CaM kinase was suggested to stimulate SR-
Ca
2q-ATPase activity and calcium transport though an
increase in V without any apparent change in the affin- max
wx ity of the ATPase for calcium 59,60 . However, more
recently it was shown by Odermatt et al. that V of the max
SR-Ca
2q-ATPase is not altered by CaM kinase-dependent
phosphorylation or by interaction with phospholamban.
Both CaM kinase- and protein kinase A-dependent phos-
phorylation shifted the K for calcium-dependence of 0.5
wx calcium transport 61 .There are no isoforms of phospho-
lamban, and the same protein is expressed in cardiac and
wx slow twitch skeletal muscle 62 .
5.1. SR-Ca
2q-ATPase in failing animal myocardium
Abundance of SR-Ca
2q-ATPase was studied in differ-
. ent animal models of myocardial failure Table 3 . Kuo et
al. showed decreased gene expression of SR-Ca
2q-ATPase
wx in Syrian hamsters with hereditary cardiomyopathy 63 .
Alteration in gene expression preceded any noticeable
myocyte damage in this model.
In a rat model of myocardial infarction induced by
occluding the left coronary artery for 4,8 and 16 weeks,
SR-Ca
2q-ATPase mRNA- and protein levels decreased
continuously with increasing severity of congestive heart
failure. Interestingly, SR-Ca
2q-ATPase activity was found
to be more depressed than expected from the reduction in
wx protein levels 64 .
In left ventricular myocardium from rats with ascending
aortic banding, a decrease in SR-Ca
2q-ATPase mRNA
levels by the polymerase chain reaction occurred in failing
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Table 3
Quantification of SR-Ca2q-ATPase in animal models of heart failure
Animal model Alteration Method Reference
wx Syrian hamster y Northern blot Kuo et al. Biochim. Biophys. Acta 1138;1992 63
wx Rat, infarction y Northern blot Zarain-Herzberg et al. Mol. Cell. Biochem. 163r164; 1996 64
Rat, infarction y Western blot idem
wx Rat, aortic banding y PCR Feldman et al. Circ. Res. 73;1993 65
wx Rat, aged SHR n.s. Northern blot Boluyt et al. Circ. Res. 75;1994 66
wx Guinea pig, aortic banding y Western blot Kiss et al. Circ. Res. 77;1995 67
wx Dog, pacing tachycardia n.s. PCR Williams et al. Circ. Res. 75;1994 68
wx Dog, pacing tachycardia y Western blot O’Rourke et al. Circulation in press 1997 69
animals after 20 weeks of banding but not in nonfailing
wx hypertrophied hearts 65 . From this data it was suggested
that the decrease in SR-Ca
2q-ATPase mRNA levels may
be a marker of the transition from compensated hypertro-
wx phy to failure in this model 65 . Of note, in another rat
failure model no decrease in mRNA levels was found
during the transition from compensated hypertrophy to
wx failure 66 . In this study, the transition to failure was
associated with significant alterations in expression of
genes encoding extracellular matrix.
A decrease in SR-Ca
2q-ATPase protein levels was ob-
served in failing guinea pig hearts following 8 weeks of
banding of the descending thoracic aorta as compared to
an age matched banded group without clinical signs of
wx heart failure 67 .
Expression of calcium cycling proteins has also been
studied in left ventricular endocardial biopsies from dogs
at baseline and at the onset of pacing tachycardia-induced
heart failure. SR-Ca
2q-ATPase mRNA levels did not sig-
nificantly change from baseline, despite development of
wx heart failure 68 . In contrast, more recently a significant
decrease in SR-Ca
2q-ATPase protein levels was observed
wx in dogs with pacing-tachycardia failure 69 . The latter
finding is consistent with measurements from Cory et al.
showing a decreased activity of the SR calcium pump in
mongrel dogs with pacing-induced heart failure and in
wx Doberman Pinscher dogs with dilated cardiomyopathy 70 .
5.2. SR-Ca
2q-ATPase in failing human myocardium
In all studies on SR-Ca
2q-ATPase mRNA levels pub-
lished by now it has been reported that mRNA levels of
SR-Ca
2q-ATPase are reduced in the failing compared to
. the nonfailing human heart Table 4 . Consistently, several
studies indicated that SR calcium uptake or SR-Ca
2q-
ATPase activity are reduced in the failing human my-
wx ocardium 75–77 . This, however, was not observed by
wx Movsesian et al. 78 . At the level of the protein findings
. have been controversial Table 4 . Interestingly, a signifi-
cant correlation between SR-Ca
2q-ATPase protein levels
and myocardial function, which was assessed by the
wx force-frequency relation, has been found 76 . This analy-
sis indicated that a wide variation exists in protein levels
of SR-Ca
2q-ATPase within the group of failing hearts
. protein levels differed by a factor of four and that this
variation in protein levels matches with differences in
myocardial function. In other words, in a subgroup of
failing hearts SR-Ca
2q-ATPase protein levels are similar to
that in nonfailing hearts and this is associated with pre-
served myocardial systolic function by force-frequency
wx relation 76 .
Table 4
Quantification of SR-Ca2q-ATPase in human heart failure
Quantity Disease Method Reference
wx 45%y DCM, ICM Northern blot Mercadier et al. J. Clin. Invest. 85;1990 71
wx 50%y DCM, ICM Northern blot Takahashi et al. Circ. Res. 71;1992 72
wx Inverse Relation With ANF DCM Northern blot Arai et al. Circ Res 72;1993 32
wx 50%y DCM, ICM Northern blot Studer et al. Circ. Res. 75;1994 73
wx 50–60%y DCM, ICM Northern blot Linck et al. Cardiovasc. Res. 31;1996 74
wx 54%y DCM Northern blot Schwinger et al. Circulation 92;1995 75
wx 40%y DCM, ICM Western blot Studer et al. Circ. Res. 75;1994 73
wx 36%y DCM, ICM Western blot Hasenfuss et al. Circ. Res. 75;1994 76
wx 33%y DCM Western blot Meyer et al. Circulation 92;1995 34
wx n.s. DCM Western blot Movsesian et al. Circulation 90;1994 49
wx n.s. DCM Western blot Schwinger et al. Circulation 92;1995 75
wx n.s. DCM, ICM Western blot Linck et al. Cardiovasc. Res. 31;1996 74
ANFsatrial natriuretic factor; DCMsdilated cardiomyopathy; ICMsischemic cardiomyopathy; n.s.sno significant change versus nonfailing human
myocardium.
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Table 5
Quantification of phospholamban in human heart failure
Quantity Disease Method Reference
wx y DCM PCR Feldman et al. Circulation 83;1991 79
wx 27–35%y DCM, ICM Northern blot Linck et al. Cardiovasc. Res. 31;1996 74
wx Inverse Relation With ANF DCM, ICM Northern blot Arai et al. Circ. Res. 72;1993 32
wx 46%y DCM Northern blot Schwinger et al. Circulation 92;1995 75
wx n.s. DCM Western blot Movsesian et al. Circulation 90;1994 49
wx 18%y DCM Western blot Meyer et al. Circulation 92;1995 34
wx n.s. DCM, ICM Western blot Linck et al. Cardiovasc. Res. 31;1996 74
wx n.s. DCM Western blot Schwinger et al. Circulation 92;1995 75
ANFsatrial natriuretic factor; DCMsdilated cardiomyopathy; ICMsischemic cardiomyopathy; n.s.sno significant change versus nonfailing human
myocardium; PCRspolymerase chain reaction.
5.3. Phospholamban in heart failure
There is little data available on phospholamban expres-
sion in animal models of myocardial failure. In left ven-
tricular endomyocardial biopsies from dogs with pacing
tachycardia-induced heart failure no change in phospho-
lamban mRNA levels was observed at the onset of clinical
wx heart failure compared to baseline 68 . In contrast, in the
guinea pig failure model due to descending thoracic aorta
banding, a decrease in phospholamban protein levels was
associated with the development of overt clinical heart
wx failure 67 .
Previous reports on alterations in mRNA and protein
levels in failing versus nonfailing human hearts are given
in Table 5. While a decrease in phospholamban mRNA
levels has been consistently observed, only one study
showed a small decrease in phospholamban protein levels
relative to total protein in failing dilated cardiomyopathy
wx 34 . However, when phospholamban was normalized to
calsequestrin, no difference existed between failing and
wx nonfailing myocardium 34 .
Interestingly, in the study by Meyer et al. SR-Ca
2q-
ATPase protein levels were decreased to a greater propor-
tion than protein levels of phospholamban in the failing
wx myocardium 34 . If we assume that the stoichiometry of
phospholamban to SR-Ca
2q-ATPase determines the level
of SR-Ca
2q-ATPase inhibition, this finding may indicate
that in the basal low phosphorylated state inhibition of
SR-Ca
2q-ATPase is more pronounced in the failing com-
wx pared to nonfailing human myocardium 80 . This could be
one possibility to explain the finding of reduced activity of
SR-Ca
2q-ATPase in failing compared to nonfailing human
wx myocardium 75 .
6. Sarcolemmal calcium pump
The sarcolemmal calcium pump is not homologous with
the SR-Ca
2q-ATPase and has a different ATP to calcium
wx stoichiometry 81 . Rate of calcium transport by this pump
seems to be small compared to that of SR-CA
2q-ATPase,
and therefore, this pump is not considered to quantitatively
contribute to beat to beat calcium elimination and myocar-
wx dial relaxation 82 . Data on expression or function of the
sarcolemmal calcium pump in human myocardium are not
available.
7. Sarcolemmal sodium-calcium exchanger
The Na
q-Ca
2q-exchanger is the dominant myocardial
calcium efflux mechanism which contributes significantly
to relaxation. The Na
q-Ca
2q-exchanger extrudes one cal-
cium ion for three sodium ions using the electrochemical
 wx wx . sodium gradient for review see 83 and 84 . In this
mode, it produces a net movement of charge resulting in a
net inward current. The Na
q-Ca
2q-exchanger is also volt-
age dependent and can reverse its mode during the action
 wx wx . potential for review see 83 and 85 . Under experimen-
tal conditions with high intracellular sodium levels, the
Na
q-Ca
2q-exchanger can promote calcium influx suffi-
wx ciently to induce excitation-contraction coupling 86 . There
are at least three different genes coding for different
Na
q-Ca
2q-exchanger molecules and a number of splice
 wx . variants has been described for review see 83 . Whether
or not an isoform shift occurs in hypertrophied or failing
myocardium is not known.
7.1. Na
q-Ca
2q-exchanger in animal models of failure
During normal cardiac development, reciprocal changes
in expression of sarcolemmal Na
q-Ca
2q-exchanger and
2q wx SR-Ca -ATPase have been described 87 . In both rat and
rabbit myocardium, exchanger mRNA levels peak near
wx birth and decline postnatally 87,88 .
Little data is available on alteration of the Na
q-Ca
2q-
exchanger in animal models of hypertrophy and failure. In
rat cardiac hypertrophy, a decreased activity as assessed by
Na
q-dependent
45Ca
2q transport was observed by Hanf et
wx al. 89 . In contrast, from electrophysiological measure-
ments in the cardiomyopathic Syrian hamster, enhanced
q 2q wx activity of the Na -Ca -exchanger was suggested 90 .
Recent studies indicate that Na
q-Ca
2q-exchanger pro-
tein levels are significantly increased in failing my-
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ocardium from dogs with pacing tachycardia-induced heart
wx failure 69 .
7.2. Na
q-Ca
2q-exchanger in human heart failure
While preliminary data from pooled human hearts did
not reveal significant changes of Na
q-Ca
2q-exchanger
wx mRNA levels in failing hearts 91 , Studer et al. showed
that mRNA as well as protein levels are significantly
wx increased in the failing human heart 73 . This finding was
wx recently confirmed by Flesch et al. 92 . Accordingly, it
was shown that Na
q-Ca
2q-exchange activity is increased
wx in myocardium from failing hearts 93 . Functional rele-
vance of increased Na
q-Ca
2q-exchanger expression is evi-
dent from a recent study showing that diastolic perfor-
mance of failing human myocardium correlates with pro-
q 2q wx tein levels of Na -Ca -exchanger 94 .
8. Interpretation of the data available on calcium-regu-
latory proteins in heart failure
8.1. Comparison of different studies
A great number of functional studies have suggested
that altered calcium handling may be of significant rele-
vance for the pathophysiology of myocardial failure in
various animal models as well as in human heart failure.
However, studies on alterations of calcium-regulatory pro-
teins have been rather controversial. At least five variables
may underlie these discrepant findings. First, pathophysiol-
ogy of myocardial failure clearly is different between the
various heart failure models. Quite obviously, subcellular
defects underlying myocardial failure in the inherited car-
diomyopathy of the Syrian hamster or subsequent to dox-
orubicin toxicity may be different from models of pressure
or volume overload or tachycardia pacing-induced heart
failure. The second variable of note is the molecular level
which is studied. Steady-state mRNA levels cannot neces-
sarily be assumed to be representative of protein levels, in
particular because both mRNA and protein synthesis or
wx degradation may be altered in the failing heart 33,74,75 .
Furthermore, protein levels do not necessarily change in
parallel with ligand binding data. This was demonstrated in
a recent study showing unchanged RyR protein levels in
failing human myocardium but a two-fold increase in the
w3 x number of high affinity H ryanodine binding sites. It was
suggested that this discrepancy may be due to regulatory
wx factors which may modulate the RyR 33 . Along this line,
alterations in protein function may occur without changes
in protein levels or ligand binding data. This may result
from altered stoichiometry of a calcium handling protein
and a regulatory protein, i.e. changes of protein levels of
the SR-Ca
2q-ATPase relative to its regulatory protein
wx phospholamban 34 . Alternatively, alterations in function
may result from isoform shifts or other modifications of
the protein. Of note, in a study by Schwinger et al.,
although protein levels of SR-Ca
2q-ATPase were un-
changed, activity of the pump and SR calcium uptake were
wx decreased in the failing human heart 75 . The third impor-
tant variable within one specific failure model is the time
point at which measurements are performed: In the Syrian
hamster cardiomyopathy model the number of L-type cal-
cium channels seems to depend on the age of the animals
wx 5 . In the pacing tachycardia dog failure model,
w3 x H ryanodine binding was decreased already after 1 day
of pacing and remained depressed at similar levels when
wx heart failure became manifest at 4 to 7 weeks 12 . In rats
with congestive heart failure due to myocardial infarction,
SR-Ca
2q-ATPase mRNA levels decreased continuously
wx during 16 weeks after infarction 64 . Finally, in rats and
guinea pigs with chronic aortic banding a decrease in
SR-Ca
2q-ATPase mRNA- or protein levels only occurred
wx in animals with overt clinical signs of heart failure 65,67 .
The fourth variable is the nature of the preparation studied:
Because of fractionating artefacts, differences between fail-
ing and nonfailing myocardium may depend on whether
crude homogenates or partially purified membrane prepa-
rations are studied. Accordingly, in the study by Schwinger
et al, SR-Ca
2q-ATPase activity and SR calcium uptake
were decreased in crude membrane preparations but not in
isolated SR vesicles from failing compared to nonfailing
wx human hearts 75 . Furthermore, the region from which the
sample is obtained may be of great relevance. This is
obvious from a recent study showing that a transmural
gradient of SR-Ca
2q-ATPase mRNA and protein levels
exists in the failing human heart with lower levels in the
wx subendocardial region 95 . The fifth variable, which is of
critical relevance for studies in human heart failure, is the
clinical situation of the patient: This includes etiology of
the disease, duration of heart failure, course of the disease,
accompanying diseases, and drug therapy. It seems manda-
tory that these factors are carefully considered when differ-
ent studies are compared or when new studies are de-
signed.
8.2. Functional releÍance of altered calcium-regulatory
proteins for the pathophysiology of human heart failure
The pathophysiology of heart failure includes altered
function at the level of myocardium, chamber remodeling,
neurohumoral activation as well as altered loading condi-
tions. The contribution of each of these factors to the
clinical syndrome of heart failure may vary depending on
the etiology and severity of the disease as well as on
therapeutic interventions. At the level of the myocardium,
disturbed SR function seems to play a central role for the
altered systolic and diastolic performance. Under physio-
logical conditions calcium released from the SR is the
dominant source for systolic activation of contractile pro-
teins. Diastolic relaxation depends on calcium removal
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from the cytosol by the SR and the sarcolemmal Na
q-
Ca
2q-exchanger. We assume that the crucial defect of
EC-coupling is a decreased capacity of the SR to accumu-
late calcium. This may result from a decreased number of
wx calcium pumps 34,35,73,76 , an increased phospholamban
wx inhibition of the pump 34 or a decreased activity of the
wx pump by other mechanisms 75 . In addition, because
SR-Ca
2q-ATPase competes with Na
q-Ca
2q-exchanger for
calcium, increased Na
q-Ca
2q-exchanger activity may con-
wx tribute to decrease SR calcium accumulation 73,92,93 .
The decreased capacity of the SR to accumulate calcium
may be of minor relevance at low heart rates. However at
higher heart rates — with a decreased time available for
calcium transport — SR calcium accumulation may be-
come inadequate, calcium release from the SR may decline
and systolic activation of contractile proteins may decrease
wx 96,97 . This is consistent with the findings of an altered
force-frequency relation, a frequency-dependent decrease
in calcium transients, and a decreased post-rest potentia-
wx tion in the failing human heart 76,98–101 . Furthermore
disturbed SR calcium loading at higher heart rates in
failing compared to nonfailing human myocardium has
wx been shown by studying rapid cooling contractures 102 .
A second consequence of decreased SR function is dias-
tolic calcium accumulation which may result in diastolic
activation of contractile proteins and disturbed diastolic
function. Because SR-Ca
2q-ATPase and Na
q-Ca
2q-ex-
changer work in concert regarding removal of calcium
from the cytosol, increased activity of the Na
q-Ca
2q-ex-
changer may compensate for decreased SR calcium trans-
port and preserve diastolic function. Accordingly, it was
shown that in failing human myocardium diastolic function
is correlated with protein levels of Na
q-Ca
2q-exchanger
wx 94 . Of course, calcium eliminated across the sarcolemma
by Na
q-Ca
2q-exchanger is no longer available for systolic
activation of contractile proteins. Furthermore, the ex-
change of one calcium ion for three sodium ions results in
an inward current which may cause electrical instability.
Therefore, alteration of calcium handling with increased
activity of Na
q-Ca
2q-exchanger relative to SR-Ca
2q-
ATPase may contribute to disturbed myocardial function
as well as to the development of arrhythmias in patients
with heart failure.
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